Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65:87–108.
Article
PubMed
Google Scholar
Portolani N, Coniglio A, Ghidoni S, Giovanelli M, Benetti A, Tiberio GAM, et al. Early and late recurrence after liver resection for hepatocellular carcinoma: prognostic and therapeutic implications. Ann Surg. 2006;243:229–35.
Article
PubMed
PubMed Central
Google Scholar
Imamura H, Matsuyama Y, Tanaka E, Ohkubo T, Hasegawa K, Miyagawa S, et al. Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy. J Hepatol. 2003;38:200–7.
Article
PubMed
Google Scholar
Tabrizian P, Jibara G, Shrager B, Schwartz M, Roayaie S. Recurrence of hepatocellular cancer after resection: patterns, treatments, and prognosis. Ann Surg. 2015;261:947–55.
Article
PubMed
Google Scholar
Furman MJ, Lambert LA, Sullivan ME, Whalen GF. Rational follow-up after curative cancer resection. J Clin Oncol. 2013;31:1130–3.
Article
PubMed
Google Scholar
Llovet JM, Ducreux M, Lencioni R, Di Bisceglie AM, Galle PR, Dufour JF, et al. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2012;56:908–43.
Article
Google Scholar
Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology. 2011;53(3):1020–2.
Article
PubMed
PubMed Central
Google Scholar
NCCNorg. NCCN clinical practice guidelines in oncology. 2013. http://www.nccn.org/professionals/physician_gls/f_guidelines.asp#site. Accessed 20 Oct 2016.
Verslype C, Rosmorduc O, Rougier P. Hepatocellular carcinoma: ESMO-ESDO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2012;23:vii41–8.
Article
PubMed
Google Scholar
Hatzaras I, Bischof DA, Fahy B, Cosgrove D, Pawlik TM. Treatment options and surveillance strategies after therapy for hepatocellular carcinoma. Ann Surg Oncol. 2014;21:758–66.
Article
PubMed
Google Scholar
Cai MY, Wang FW, Li CP, Yan LX, Chen JW, Luo RZ, et al. Prognostic factors affecting postoperative survival of patients with solitary small hepatocellular carcinoma. Chin J Cancer. 2016;35:80.
Article
PubMed
PubMed Central
Google Scholar
He W, Li B, Zheng Y, Zou R, Shen J, Cheng D, et al. Resection vs. ablation for alpha-fetoprotein positive hepatocellular carcinoma within the Milan criteria: a propensity score analysis. Liver Int. 2016;36:1677–87.
Article
PubMed
CAS
Google Scholar
Qiu J, Peng B, Tang Y, Qian Y, Guo P, Li M, et al. CpG methylation signature predicts recurrence in early-stage hepatocellular carcinoma: results from a multicenter study. J Clin Oncol. 2017;35:734–42.
Article
PubMed
CAS
Google Scholar
Boulin M, Lejeune C, Le Teuff G, Binquet C, Bouvier AM, Bedenne L, et al. Patterns of surveillance practices after curative surgery for colorectal cancer in a French population. Dis Colon Rectum. 2005;48:1890–9.
Article
PubMed
Google Scholar
Trinchet JC, Chaffaut C, Bourcier V, Degos F, Henrion J, Fontaine H, et al. Ultrasonographic surveillance of hepatocellular carcinoma in cirrhosis: a randomized trial comparing 3- and 6-month periodicities. Hepatology. 2011;54:1987–97.
Article
PubMed
Google Scholar
Lu WL, Jansen L, Post WJ, Bonnema J, Van De Velde JC, De Bock GH. Impact on survival of early detection of isolated breast recurrences after the primary treatment for breast cancer: a meta-analysis. Breast Cancer Res Treat. 2009;114(3):403–12.
Article
PubMed
CAS
Google Scholar
Pita-Fernández S, Alhayek-Aí M, González-Martín C, López-Calviño B, Seoane-Pillado T, Pértega-Díaz S. Intensive follow-up strategies improve outcomes in nonmetastatic colorectal cancer patients after curative surgery: a systematic review and meta-analysis. Ann Oncol. 2015;26:644–56.
Article
PubMed
Google Scholar
Barone C, Nuzzo G, Cassano A, Basso M, Schinzari G, Giuliante F, et al. Final analysis of colorectal cancer patients treated with irinotecan and 5-fluorouracil plus folinic acid neoadjuvant chemotherapy for unresectable liver metastases. Br J Cancer. 2007;97:1035–9.
Article
PubMed
PubMed Central
CAS
Google Scholar
Adam R, Wicherts DA, De Haas R, Ciacio O, Levi F, Paule B, et al. Patients with initially unresectable colorectal liver metastases: is there a possibility of cure? J Clin Oncol. 2009;27:1829–35.
Article
PubMed
Google Scholar
Kopetz S, Chang GJ, Overman MJ, Eng C, Sargent DJ, Larson DW, et al. Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy. J Clin Oncol. 2009;27:3677–83.
Article
PubMed
PubMed Central
Google Scholar
Chia SK, Speers CH, D’yachkova Y, Kang A, Malfair-Taylor S, Barnett J, et al. The impact of new chemotherapeutic and hormone agents on survival in a population-based cohort of women with metastatic breast cancer. Cancer. 2007;110:973–9.
Article
PubMed
Google Scholar
Benamore R, Shepherd FA, Leighl N, Pintilie M, Patel M, Feld R, et al. Does intensive follow-up alter outcome in patients with advanced lung cancer? J Thorac Oncol. 2007;2:273–81.
Article
PubMed
Google Scholar
Sheffield KM, Crowell KT, Lin Y-L, Djukom C, Goodwin JS, Riall TS. Surveillance of pancreatic cancer patients after surgical resection. Ann Surg Oncol. 2012;19:1670–7.
Article
PubMed
Google Scholar
Li Y-J, Lei Y-H, Yao N, Wang C-R, Hu N, Ye W-C, et al. Autophagy and multidrug resistance in cancer. Chin J Cancer. 2017;36:52.
Article
PubMed
PubMed Central
Google Scholar
Soini Y, Virkajärvi N, Raunio H, Pääkkö P. Expression of P-glycoprotein in hepatocellular carcinoma: a potential marker of prognosis. J Clin Pathol. 1996;49:470–3.
Article
PubMed
PubMed Central
CAS
Google Scholar
Caruso ML, Valentini AM. Overexpression of p53 in a large series of patients with hepatocellular carcinoma: a clinicopathological correlation. Anticancer Res. 1999;19:3853–6.
PubMed
CAS
Google Scholar
Pohl A, Lage H, Müller P, Pomorski T, Herrmann A. Transport of phosphatidylserine via MDR1 (multidrug resistance 1) P-glycoprotein in a human gastric carcinoma cell line. Biochem J. 2002;365:259–68.
Article
PubMed
PubMed Central
CAS
Google Scholar
Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc J-F, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359:378–90.
Article
PubMed
CAS
Google Scholar
Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009;10:25–34.
Article
PubMed
CAS
Google Scholar
Liu D, Fong DYT, Chan ACY, Poon RTP, Khong P-L. Hepatocellular carcinoma: surveillance CT schedule after hepatectomy based on risk stratification. Radiology. 2015;274:133–40.
Article
PubMed
Google Scholar
Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, et al. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66:115–32.
Article
PubMed
Google Scholar